Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Livea vs MedLeanRx

Livea
Graded #115

Lower grade

vs+4.200000000000003
MedLeanRx
Graded #66

Higher grade

The verdict

MedLeanRx takes it — 73.9/100 to 69.7/100.

MedLeanRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedLeanRx +20
54
74
Dose & formulationMedLeanRx +29
64
93
Clinical oversightLivea +16
93
77
Labs & monitoringLivea +21
73
52
FulfillmentLivea +2
79
77
Contract termsEven
55
55
Livea · left barMedLeanRx · right bar

The numbers

MetricLiveaMedLeanRx
WeighScore69.7/10073.9/100
GradeCC
Scorecard rank#115#66
Semaglutide$99/mo (plus a separate fee, compounded)$149/mo (starting dose, promotional rate, compounded)
Tirzepatide$199/mo (compounded)$269/mo (starting dose, compounded)
Coverage4 states1 state
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Livea

Graded #115 · C

Strengths

  • LegitScript certified; physician-owned Livea Medical PLLC; Medical Director Dr. Paul Olson, internal medicine/nephrology, 40 years experience
  • Compounded sema from $99/mo and tirz from $199/mo — significantly cheaper than brand Ozempic/Wegovy ($1,000+/mo self-pay)
  • Comprehensive program: InBody scans, registered dietitian nutrition counseling, health coaching, and regular provider check-ins included
  • 15+ years established (founded 2011); 50,000+ clients served; voted Minnesota's Best Weight Loss Program 5 consecutive years
  • Medications shipped to door; same-day consultations; in-person or telehealth; typically HSA/FSA eligible

Where it loses points

  • Telehealth limited to 4 states only (MN, WI, IA, FL) — unavailable to most of the US; primarily a regional clinic network
  • Pricing ambiguous: $69/mo program fee plus separate medication cost ($99/mo sema) may bring GLP-1 total to ~$168/mo
  • Compounded tirzepatide availability uncertain — FDA announced shortage end in 2026; access subject to eligibility
  • Labs (bloodwork) not explicitly included in any published program tier; confirmed at consultation only
  • Strong MN/WI clinic focus; telehealth reach into IA and FL is newer and less established than core markets
MedLeanRx

Graded #66 · C

Strengths

  • Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
  • Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
  • Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
  • LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
  • Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips

Where it loses points

  • Texas only — not available in the other 49 states
  • Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
  • Strict no-refund policy: 'All sales are final' per Terms & Conditions
  • Pharmacy partner not publicly named — a transparency gap for a compounding service
  • Legal entity name and founding details not published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard